Does Separate Administration of Montelukast and Levocetirizine Provide Better Results in Perennial Allergic Rhinitis: A Hospital Based Study

  • Sumit ChattopadhyayEmail author
  • Aloke Bose Majumdar
  • Arup Sengupta
  • Dipayan Biswas
  • Ayon Pal
  • Nilanjan Dastidar
Original Article


To determine whether separate administration of Montelukast and Levocetirizine provide a better response in perennial allergic rhinitis (PAR) than their fixed dose combination. Total 151 patients underwent a hospital based clinical study, being divided in 3 discrete groups. One group was given non-bilayered combination of Montelukast and Levocetrizine, 2nd group was given their bilayered counterpart whereas 3rd group was given the drugs at 12 h interval. Medications were continued for 3 months before stoppage. All patients were followed up for 1 month more to note recurrence of symptoms of PAR on weekly basis. While the combination formulation gave 9.8 and 12.6 % symptom-free patients; separate administration of the molecules gave 43.3 % positive (symptom-free 1 month) result. Fixed-dose combination is found to cause 1.4 times more chance of recurrence. Though per se, Montelukast and Levocetrizine does not give excellent response in PAR, their separate administration provides better outcome. So a morning dose of Montelukast and Levocetirizine at bed time is recommended while treating PAR.


Perennial allergic rhinitis PAR Montelukast Levocetirizine 


Compliance with ethical standards

Conflict of interest



  1. 1.
    Sinha B, Vibha Singla R, Chowdhury R (2015) Allergic rhinitis: a neglected disease—a community based assessment among adults in Delhi. J Postgrad Med 61:169–175CrossRefPubMedGoogle Scholar
  2. 2.
    Ciebada M, Dubuske LM Combined therapy of Montelukast and antihistaminics improves quality of life in patients with perennial allergic rhinitis: a double blind placebo controlled study. J Allergy Clin Immunol. doi: 10.1016/j.jaci2005.12.657
  3. 3.
    Roshdy HM (2015) Cytogenetic and mutagenic effect of Levocetirizine and Monteleukast alone or in combination on pregnant mice and embryos. Res J Pharm Biol Chem Sci 6(3):979–988Google Scholar
  4. 4.
    Raju K, Elumalai A, Sridhar E (2013) Topic irrational drug combination. Int J Exp Pharmacol 3(2):52–56Google Scholar
  5. 5.
    Rathode RT, Mishra D (2009) FDC of montelukast with levocetirizine: focus on bilayer technology. J Indian Med Assoc 107(8):562–564Google Scholar
  6. 6.
    Gupta MM, Singla L, Soni PK (2013) Topic formulation development of oral dispersible tablet containing paracetamol, Montelukast and Levocetirizine dihydrochloride. Pharmacol Innov J 2(2)Google Scholar
  7. 7.
    Database US National Institute of Health, Study at Republic of Korea, July 2012–Feb 2013, Soonchunyaang University Buchen Hospital, Trial no NCT 01640535, clinicaltrials.govGoogle Scholar
  8. 8.
    Benninger MS, Waters H (2009) Montelukast: pharmacology, safety, tolerability and efficacy. Clin Med Ther 1:1253–1261Google Scholar
  9. 9.
    Recommendations of New Drug advisory Committee (NDAC) (Pulmonary) held on 03.12.2011Google Scholar
  10. 10.
    Rubinstein I, Kumar B, Schriever C (2004) Long term therapy of Montelukast and Levocetirizine—a preliminary observation. Respir Med 98(2):134–138CrossRefPubMedGoogle Scholar
  11. 11.
    Greiner AN, Meltzer EO (2011) Overview of the treatment of allergic rhinitis and nonallergic rhinopathy. Topic overview of treatment allergic rhinitis and non allergic rhinopathy. In: Proceedings of the American Thoracic Society, vol 8, no. 1, pp 121–131Google Scholar

Copyright information

© Association of Otolaryngologists of India 2015

Authors and Affiliations

  1. 1.Department of ENTMGM Medical CollegeKishanganjIndia
  2. 2.Department of Health and Family WelfareGovernment of West BengalKolkataIndia
  3. 3.Department of PharmacologyMGM Medical CollegeKishanganjIndia

Personalised recommendations